Summary

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. GLP-1 analogue drugs have witnessed significant acceptance, particularly after their benefits in chronic obesity and weight management became widely known. This class of drugs, referred to as incretin mimetics, aids in regulating blood glucose levels and promoting satiety, making them crucial in treating diabetes and obesity. The market is driven by a strong R&D pipeline, with many key players developing innovative products and novel indications.

The GLP-1 analogues market is experiencing robust growth due to a strong research and development (R&D) pipeline aimed at advancing treatments for type 2 diabetes and obesity. Pharmaceutical companies are heavily investing in developing new and improved GLP-1 receptor agonists to enhance efficacy, safety, and patient convenience. For example, Novo Nordisk is exploring once-weekly oral formulations of semaglutide, which have shown promising results in reducing HbA1c levels and promoting weight loss. Additionally, Eli Lilly's tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated superior efficacy in clinical trials compared to existing GLP-1 therapies. These advancements are fueling the market's expansion, as companies strive to address the growing global burden of diabetes and obesity. Moreover, the extended therapeutic uses and development of oral GLP-1 Analogues present various lucrative opportunities over the forecast years. However, the high entry barriers due to duopoly and non-adherence to therapy are challenging the market growth throughout the forecast period of 2024-2032.


The key regions considered for Global GLP-1 Analogues Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global GLP-1 Analogues Market in terms of revenue. The market growth in the region is being attributed to factors including the high prevalence of type 2 diabetes and obesity, advanced healthcare infrastructure, and the strong presence of key pharmaceutical companies such as Novo Nordisk, Eli Lilly, and Pfizer. Whereas, the market in the Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by the increasing prevalence of diabetes and obesity, rising healthcare awareness, and improving access to advanced medical treatments. Countries such as China and India are witnessing a surge in diabetes cases due to urbanization, sedentary lifestyles, and changing dietary habits, driving the demand for effective diabetes management solutions.

Major market player included in this report are:
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
AstraZeneca
Boehringer Ingelheim International GmbH
Innovent
Hanmi Pharm
Zealand Pharma A/S
Pfizer, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Roche Holding AG

The detailed segments and sub-segment of the market are explained below:
By Product:
Ozempic
Wegovy
Rybelsus
Saxenda
Victoza
Trulicity
Mounjaro
Zepbound
Soliqua
Xultophy
Bydureon
Other products
By Format:
Single-dose
Multi-dose
Tablets

By Route of Administration:
Subcutaneous
Oral

By Indication:
Diabetes
Obesity
Other indications

By End User:
Hospitals and Specialty Clinics
Long-term Care Facilities
Home Care Settings

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico
Rest of Latin America

Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Global GLP-1 Analogues Market Executive Summary
1.1. Global GLP-1 Analogues Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Format
1.3.3. By Route of Administration
1.3.4. By Indication
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global GLP-1 Analogues Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global GLP-1 Analogues Market Dynamics
3.1. Market Drivers
3.1.1. Strong R&D Pipeline
3.1.2. Increasing Prevalence of Chronic Diseases
3.2. Market Challenges
3.2.1. High Entry Barriers Due to Duopoly
3.2.2. Non-adherence to Therapy
3.3. Market Opportunities
3.3.1. Extended Therapeutic Uses
3.3.2. Development of Oral GLP-1 Analogues

Chapter 4. Global GLP-1 Analogues Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global GLP-1 Analogues Market Size & Forecasts by Product 2022-2032
5.1. Segment Dashboard
5.2. Global GLP-1 Analogues Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Ozempic
5.2.2. Wegovy
5.2.3. Rybelsus
5.2.4. Saxenda
5.2.5. Victoza
5.2.6. Trulicity
5.2.7. Mounjaro
5.2.8. Zepbound
5.2.9. Soliqua
5.2.10. Xultophy
5.2.11. Bydureon
5.2.12. Other products

Chapter 6. Global GLP-1 Analogues Market Size & Forecasts by Format 2022-2032
6.1. Segment Dashboard
6.2. Global GLP-1 Analogues Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Single-dose
6.2.2. Multi-dose
6.2.3. Tablets

Chapter 7. Global GLP-1 Analogues Market Size & Forecasts by Route of Administration 2022-2032
7.1. Segment Dashboard
7.2. Global GLP-1 Analogues Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Subcutaneous
7.2.2. Oral

Chapter 8. Global GLP-1 Analogues Market Size & Forecasts by Indication 2022-2032
8.1. Segment Dashboard
8.2. Global GLP-1 Analogues Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Diabetes
8.2.2. Obesity
8.2.3. Other indications

Chapter 9. Global GLP-1 Analogues Market Size & Forecasts by End User 2022-2032
9.1. Segment Dashboard
9.2. Global GLP-1 Analogues Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospitals and Specialty Clinics
9.2.2. Long-term Care Facilities
9.2.3. Home Care Settings

Chapter 10. Global GLP-1 Analogues Market Size & Forecasts by Region 2022-2032
10.1. North America GLP-1 Analogues Market
10.1.1. U.S. GLP-1 Analogues Market
10.1.1.1. Product breakdown size & forecasts, 2022-2032
10.1.1.2. Format breakdown size & forecasts, 2022-2032
10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.4. Indication breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada GLP-1 Analogues Market
10.2. Europe GLP-1 Analogues Market
10.2.1. U.K. GLP-1 Analogues Market
10.2.2. Germany GLP-1 Analogues Market
10.2.3. France GLP-1 Analogues Market
10.2.4. Spain GLP-1 Analogues Market
10.2.5. Italy GLP-1 Analogues Market
10.2.6. Rest of Europe GLP-1 Analogues Market
10.3. Asia-Pacific GLP-1 Analogues Market
10.3.1. China GLP-1 Analogues Market
10.3.2. India GLP-1 Analogues Market
10.3.3. Japan GLP-1 Analogues Market
10.3.4. Australia GLP-1 Analogues Market
10.3.5. South Korea GLP-1 Analogues Market
10.3.6. Rest of Asia Pacific GLP-1 Analogues Market
10.4. Latin America GLP-1 Analogues Market
10.4.1. Brazil GLP-1 Analogues Market
10.4.2. Mexico GLP-1 Analogues Market
10.4.3. Rest of Latin America GLP-1 Analogues Market
10.5. Middle East & Africa GLP-1 Analogues Market
10.5.1. Saudi Arabia GLP-1 Analogues Market
10.5.2. South Africa GLP-1 Analogues Market
10.5.3. Rest of Middle East & Africa GLP-1 Analogues Market

Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. Company 1
11.1.2. Company 2
11.1.3. Company 3
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Novo Nordisk A/S
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Eli Lilly and Company
11.3.3. Sanofi
11.3.4. AstraZeneca
11.3.5. Boehringer Ingelheim International GmbH
11.3.6. Innovent
11.3.7. Hanmi Pharm
11.3.8. Zealand Pharma A/S
11.3.9. Pfizer, Inc.
11.3.10. GlaxoSmithKline plc
11.3.11. Johnson & Johnson
11.3.12. Merck & Co., Inc.
11.3.13. Teva Pharmaceutical Industries Ltd.
11.3.14. Bristol-Myers Squibb Company
11.3.15. Roche Holding AG

Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes